HUM00189911 Op	otimization of TEA Modalities fo	or Treatment of IBS-C
Visit # (1-5)	SUBJECT ID: OC	VISIT DATE: 7 27 21
	ONSENT SIGNED: 7_1271_[
Demographics		·
Sex: □ M 🗹 F Y	ear of birth: 2001 height: _	5 ft <u>7</u> in Weight: <u>60</u> lbs
Race:		Ethnicity:
□White	marican	□Hispanic or Latino
□Native Hawaiian o	r Other Pacific Islander	✓Not Hispanic or Latino □Unknown
□Asian	100000000000000000000000000000000000000	DOTATION
□American Indian o	r Alaska Native	
□Unknown		
Initials and Date: We discuss 05 fue ni The Gubseck	sks and requirem	exts of TEAW Rarestat.
Eligibility Criter	<u>ia</u>	
Inclusion Criteria: In of the following crit	n order to be eligible to participa eria:	ate in this study, a study participant must meet <u>all</u>
✓ Yes 🗆 No	Male or female, aged 18 to 99	
D∕Yes □ No	Willing to comply with all stud the study	y procedures and be available for the duration of
yes □ No	Diagnosed with IBS-C satisfying	g Rome IV criteria (Survey completed by subject)
y Yes □ No	Have symptoms present for at	least the last 3 months
prYes □ No	Have abdominal pain that is no	ot adequately relieved at the time of screening

CRA Signature:

⊈Yes □ No

_Date: <u>7/27/2</u>/

Has a VAS pain score of >3 (on 0-10 score)

Rome IV Criteria for IBS	
Recurrent abdominal pain on average at least 1 day/week in the last 3 months related to defecation.	Yes □ No
Recurrent abdominal pain on average at least 1 day/week in the last 3 months associated with a change in frequency of stool.	≱Yes □ No
Recurrent abdominal pain on average at least 1 day/week in the last 3 months associated with a change in form (appearance) of stool.	Yes □ No

	A potential study participant who meets <u>any</u> of the following exclusion criteria at luded from participation in this study if:
□ Yes 🗖 No	Have an unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes, unstable thyroid disease
□ Yes 🗷 No	Have history of abdominal surgery (other than cholecystectomy or appendectomy)
□ Yes 🗷 No	Are taking anticoagulants or antispasmodic, antidiarrheal, or opioids or other pain relief medications and cannot stop these medications for three consecutive days before each study visit
□ Yes 🗷 No	Are pregnant or lactating; women of childbearing potential complete a pregnancy test at each visit
□ Yes 🗷 No	Have known allergic reactions to components of the ECG electrodes
□ Yes 🕫 No	Received treatment with an investigational drug or other intervention within 6 months of the date of consent
□ Yes 🗖 No	Anything that, in the opinion of the investigator, would place the study participant at increased risk or preclude the study participant's full compliance with or completion of the study
□ Yes Ø No	Are unable to provide informed consent

For women only:

Hysterectomy: □ Yes ✓ No	Post-Menopause*: □ Yes ☑ No
(If no to both of above)	*Post-menopausal is defined as no menses for the
Pregnancy test result: □ Positive Negative	previous 12 months. If cessation of menses is within 18 months then the subject should be treated as premenopausal and a pregnancy test must be performed.

CRA Signature:

Date: 7/27/2/

The subject is eligible (meets all of the inclusion criteria and meets none of the exclusion criteria)	_
True □ False	_

Procedure monitoring

Subject has not taken medications affecting the gut or pain perception for 48 hours. (anticoagulants, antispasmodic, antidiarrheal, opioids)	Subject has not had any food or drink other than water since 8 am	TEA Methods: ST36-100Hz ST36-25Hz PC6-100Hz PC6-25Hz SM-25Hz	EKG Settings: Frequency and Amplification
g∕True □ False	7⁄ True □ False	PC-6 100HZ	Frequency: 1.5 Hz Amplification: 1000

15 Minute Baseline EKG (no Stimulation or Distention)

Time of Baseline Period Start:	3:05	
Time of Baseline Period End:	3:20	
Baseline EKG Recording Filename:	01-A-1	
Baseline Recording Folder:		and the second s

Rectal Distention One without (no Sstimulation)

Time of Barostat Catheter Insertion:	3.26 3:23	
Time of Control Distention Initiation:	3:33	
Time of ***-Distention Termination:	3:40	
Distention One EKG Recording Filename:	01-A-7	
Distention One EKG Recording Folder:		

CRA Signature

Date: 7/2/2/

Rest Period	MA	
Time of Rest Period Start:		
Time of Rest Period End:		
	CB 7-27-31	

15 Minute Baseline EKG with Stimulation but no Rectal Distention

Time of Baseline Period Start:	3:49	
Time of Baseline Period End:	4:05	
Baseline EKG Recording Filename:	01-A-3	
Baseline EKG Recording Folder:		

TEA/Sham TEA Administration

Time of TEA/Sham Initiation: 3:49 Time of change in output: Time of change in output: Time of change in output:	Stimulation output (mA): 1.60 Stimulation output (mA): 1.85 Stimulation output (mA): Stimulation output (mA):	i i
---	---	--------

Rectal Distention Two (with stimulation)

Time of Mat-Distention Initiation:	4:09	
Time of Last Distention Termination:	4:17	
Time of Barostat Catheter Removal:	4:14	
Distention Two EKG Recording Filename:	01-A-4	
Distention Two EKG Recording Folder:		

CRA Signature:	 Date:	/	/	
CICA DIGITATOR				

HUM00189911 Optimization of TEA Modalities for Treatment of IBS-C

Name of Person who performed the procedure: <u>Lydia Watts</u>
Signature of Person who performed the procedure:
Date: 07 /27/2021
PI Signature
Date://

HUM00189911 Optimization of TEA Modalities for Treatment of IBS-C

CUMULATIVE ADVERSE EVENTS

At end of study only: check this box if subject experienced NO ADVERSE EVENTS

Comments (include CRA dated initials for each event)					4 = resolved with sequelae 5 = fatal 6 = unknown
Outcome Med taken				Outcome	
Reported as SAE?					1 = resolved 2 = resolving 3 = not resolved
Severity (Grade)					
Event End Date	,	_	,		
Event Onset Date	,	,	,	Reported as SAE?	1 = yes 2 = no
				on: idy Agent	4 = probable 5 = definite
Adverse Event Description				Attribution: Relation to Study Agent	1 = unrelated 2 = unlikely 3 = possible
Adverse E				Severity (Grade)	4 = life-threatening 5 = fatal
Adverse Event Reported Date				Severity	1 = mild 4 2 = moderate 5 3 = severe

CRA Signature:

9